Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable her2 positive breast cancer

Clinical Breast Cancer

Volumn 12, Issue 1, 2012, Pages 49-56

  Nakamura, Seigo ^a,b   Ando, Masashi ^c   Masuda, Norikazu ^d   Aogi, Kenjiro ^e   Ino, Hiroyo ^f   Iwata, Hiroji ^g   Tokuda, Yutaka ^h   Yamamoto, Naohito ⁱ   Kasai, Hiroi ^c   Takeuchi, Masahiko ^j   Tsuda, Hitoshi ^c   Akiyama, Futoshi ^k   Kurosumi, Masafumi ^l   Fujiwara, Yasuhiro ^c  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ CHIBA CANCER CENTER   (Japan)

^j KITASATO UNIVERSITY   (Japan)

^k CANCER INSTITUTE   (Japan)

^l SAITAMA CANCER CENTER   (Japan)

more..

Author keywords

Breast cancer; HER2; Primary systemic therapy; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; INFECTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 84856057463     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.10.002     Document Type: Article

References (31)

1. B. Fisher, J. Bryant, N. Wolmark Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 1998 2672 2685 (Pubitemid 28363030)
2. J.A. Hage, C.J.H. Velde, J.P. Julien Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902 J Clin Oncol 19 2001 4224 4237 (Pubitemid 33081640)
3. H.D. Bear, S. Anderson, A. Brown The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 2003 4165 4174 (Pubitemid 46606185)
4. P. Rastogi, S.J. Anderson, H.D. Bear Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 J Clin Oncol 26 2008 778 785 (Pubitemid 351264391)
5. V. Guarneri, K. Broglio, S.W. Kau Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 2006 1037 1044 (Pubitemid 46638799)
6. L.A. Carey, R. Metzger, E.C. Dees American Joint Committee on Cancer Tumor Node Metastasis stage after neoadjuvant chemotherapy and breast cancer outcome J Natl Cancer Inst 97 2005 1137 1142 (Pubitemid 41511213)
7. M.C. Green, A.U. Buzdar, T. Smith Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 2005 5983 5992
8. I. Smith, M. Procter, R.D. Gelber 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial Lancet 369 2007 29 36 (Pubitemid 46039831)
9. E.H. Romond, E.A. Perez, J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
10. D.J. Slamon, W. Eiermann, N. Robert Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2 positive early breast cancer patients: BCIRG 006 study Cancer Res 69 suppl 3 2009 abstract 62
11. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
12. M. Marty, F. Cognetti, D. Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group J Clin Oncol 23 2005 4265 4274 (Pubitemid 46207001)
13. A.U. Buzdar, N.K. Ibrahim, D. Francis Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 2005 3676 3685
14. L. Gianni, W. Eiermann, V. Semiglazov Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 2010 377 384
15. A.U. Buzdar, V. Valero, N.K. Ibrahim Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen Clin Cancer Res 13 2007 228 233 (Pubitemid 46121873)
16. H.J. Burstein, L.N. Harris, R. Gelman Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol 21 2003 46 53
17. J. Hurley, P. Doliny, I. Reis Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2positive locally advanced breast cancer J Clin Oncol 24 2006 1831 1838 (Pubitemid 46638980)
18. B.P. Coudert, R. Largillier, L. Arnould Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial J Clin Oncol 25 2007 2678 2684 (Pubitemid 47123173)
19. S.A. Limentani, A.M. Brufsky, J.K. Erban Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer J Clin Oncol 25 2007 1232 1238 (Pubitemid 46640569)
20. W.M. Sikov, D.S. Dizon, R. Strenger Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University oncology group study J Clin Oncol 27 2009 4693 4700
21. M. Untch, P.A. Fasching, G.E. Konecny Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy Three year median follow-up data of the TECHNO Trial Cancer Res 70 suppl 2010 165s (abstract P1-11-03)
22. R.S. Mehta, D. Hsiang, K. Lane Association between pathologic complete response and survival in patients treated with sequential anthracyclines and concomitant taxanes and trastuzumab in HER2-positive breast cancer Cancer Res 69 suppl 2009 251s (abstract 3141)
23. C. Shimizu, N. Masuda, K. Yoshimura Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer Jpn J Clin Oncol 39 2009 484 490
24. M. Toi, S. Nakamura, K. Kuroi Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival Breast Cancer Res Treat 110 2008 531 539 (Pubitemid 351962591)
25. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
26. Common Terminology Criteria for Adverse Events (CTCAE v3.0), 2003 (Japanese translation JCOG/JCSP version, 2004) [in Japanese] Int J Clin Oncol 9 suppl III 2004 1 82
27. M. Untch, M. Rezai, S. Loibl Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J Clin Oncol 28 2010 2024 2031
28. L. Gianni, T. Pienkowski, Y-H. Im Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ("NeoSphere") Cancer Res 70 suppl 2010 82s (abstract S3-2)
29. J. Baselga, I. Bradbury, H. Eidtmann First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer Cancer Res 70 suppl 2010 82s (abstract S3-3)
30. F. Peintinger, A.U. Buzdar, H.M. Kuerer Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab Ann Oncol 19 2008 2020 2025
31. G. Von Minckwitz, M. Kaufmann, S. Kuemmel Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis J Clin Oncol 29 suppl 2011 87s (abstract 1028)